In this study, we aimed to address these concerns by comparing the outcomes of patients with advanced HCC treated with AB, stratified by diverse thresholds of PD-L1 expression levels in both malignant and tumor-infiltrating cells, using a reliable and uniform antibody clone for detecting PD-L1. The gene discussed is CD274; the disease is hepatocellular carcinoma.